SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 228 filers reported holding SAGE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.20 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $461 | -56.0% | 22,220 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $1,047 | +14.2% | 22,220 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $917 | +8.1% | 22,220 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $848 | -99.9% | 22,220 | 0.0% | 0.00% | -33.3% |
| Q3 2022 | $868,000 | +22.1% | 22,220 | 0.0% | 0.00% | +50.0% |
| Q2 2022 | $711,000 | -6.7% | 22,220 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $762,000 | -16.5% | 22,220 | +2.1% | 0.00% | 0.0% |
| Q4 2021 | $913,000 | -2.2% | 21,770 | +2.4% | 0.00% | -33.3% |
| Q3 2021 | $934,000 | -20.8% | 21,270 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,179,000 | -23.5% | 21,270 | 0.0% | 0.00% | -40.0% |
| Q1 2021 | $1,541,000 | -9.3% | 21,270 | +7.9% | 0.01% | -16.7% |
| Q4 2020 | $1,699,000 | +40.3% | 19,720 | -4.8% | 0.01% | +20.0% |
| Q3 2020 | $1,211,000 | +1514.7% | 20,720 | +1909.7% | 0.01% | – |
| Q4 2019 | $75,000 | -97.6% | 1,031 | -95.3% | 0.00% | -100.0% |
| Q3 2019 | $3,134,000 | -62.4% | 21,951 | -52.5% | 0.02% | -54.8% |
| Q2 2019 | $8,342,000 | +1.3% | 46,231 | -7.4% | 0.04% | -14.3% |
| Q1 2019 | $8,233,000 | +326.6% | 49,944 | +127.4% | 0.05% | +276.9% |
| Q4 2018 | $1,930,000 | -76.6% | 21,964 | -56.0% | 0.01% | -73.5% |
| Q3 2018 | $8,233,000 | +154.8% | 49,944 | +134.7% | 0.05% | +133.3% |
| Q2 2018 | $3,231,000 | +1.4% | 21,280 | +6.1% | 0.02% | -4.5% |
| Q1 2018 | $3,186,000 | -40.4% | 20,060 | -68.4% | 0.02% | -46.3% |
| Q4 2017 | $5,349,000 | 0.0% | 63,450 | 0.0% | 0.04% | -2.4% |
| Q3 2017 | $5,349,000 | +6.8% | 63,450 | 0.0% | 0.04% | +5.0% |
| Q2 2017 | $5,009,000 | +5.2% | 63,450 | -13.6% | 0.04% | -9.1% |
| Q1 2017 | $4,762,000 | +194.3% | 73,450 | +122.2% | 0.04% | +158.8% |
| Q4 2016 | $1,618,000 | +39.6% | 33,050 | +29.9% | 0.02% | +30.8% |
| Q3 2016 | $1,159,000 | +133.2% | 25,450 | +50.1% | 0.01% | +116.7% |
| Q2 2016 | $497,000 | +15.0% | 16,950 | +22.4% | 0.01% | +20.0% |
| Q1 2016 | $432,000 | -49.7% | 13,850 | -5.5% | 0.01% | -50.0% |
| Q4 2015 | $858,000 | +41.8% | 14,650 | +2.4% | 0.01% | +42.9% |
| Q3 2015 | $605,000 | -39.9% | 14,300 | +3.6% | 0.01% | -41.7% |
| Q2 2015 | $1,007,000 | +67.0% | 13,800 | +15.0% | 0.01% | +50.0% |
| Q1 2015 | $603,000 | – | 12,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
| Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
| Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
| BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
| TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
| Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
| RA Capital Management | 350,933 | $49,569,000 | 2.65% |
| Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
| OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |